Table 1.
Patient characteristics for two cases of nephrotic syndrome treated with apixaban as thromboprophylaxis
| Characteristic | Case 1 | Case 2 |
|---|---|---|
| Age, yr | 28 | 49 |
| Sex | Female | Female |
| Serum albumin | <15 g/l | 17 g/dl |
| Urinary protein excretion | 12 g/24 h | 10 g/24 h |
| Serum cholesterol | 19.3 mmol/l | 12.6 mmol/l |
| Serum creatinine | 57 μmol/l | 253 μmol/l |
| Hemoglobin | 15.4 g/dl | 14.9 g/dl |
| PT | 14.3 s | 12.9 s |
| INR | 1.08 | 0.94 |
| aPTT | 56.2 s | 30.3 s |
| Kidney biopsy diagnosis | Minimal change nephropathy | Membranous nephropathy |
| Additional thrombosis risk | No | DVT during pregnancy 15 years prior |
| Smoking | No | No |
| DOAC used | Apixaban 5 mg BD | Apixaban 5 mg BD |
aPTT, activated partial thromboplastin time; BD, twice daily; DOAC, direct-acting oral anticoagulant; DVT, deep vein thrombosis; INR, international normalized ratio; PT, prothrombin time.